- Home
- UPST vs ACLX Comparison
UPST vs ACLX Comparison
Compare UPST & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UPST
- ACLX
- Stock Information
- Founded
- UPST 2012
- ACLX 2015
- Country
- UPST United States
- ACLX United States
- Employees
- UPST N/A
- ACLX N/A
- Industry
- UPST Finance: Consumer Services
- ACLX Biotechnology: Pharmaceutical Preparations
- Sector
- UPST Finance
- ACLX Health Care
- Exchange
- UPST Nasdaq
- ACLX Nasdaq
- Market Cap
- UPST 4.8B
- ACLX 4.4B
- IPO Year
- UPST 2020
- ACLX 2022
- Fundamental
- Price
- UPST $52.72
- ACLX $85.09
- Analyst Decision
- UPST Buy
- ACLX Strong Buy
- Analyst Count
- UPST 14
- ACLX 12
- Target Price
- UPST $74.73
- ACLX $113.08
- AVG Volume (30 Days)
- UPST 7.3M
- ACLX 548.8K
- Earning Date
- UPST 11-04-2025
- ACLX 11-07-2025
- Dividend Yield
- UPST N/A
- ACLX N/A
- EPS Growth
- UPST N/A
- ACLX N/A
- EPS
- UPST N/A
- ACLX N/A
- Revenue
- UPST $884,807,000.00
- ACLX $56,979,000.00
- Revenue This Year
- UPST $59.39
- ACLX N/A
- Revenue Next Year
- UPST $27.34
- ACLX $210.73
- P/E Ratio
- UPST N/A
- ACLX N/A
- Revenue Growth
- UPST 53.62
- ACLX N/A
- 52 Week Low
- UPST $31.40
- ACLX $47.86
- 52 Week High
- UPST $96.43
- ACLX $107.37
- Technical
- Relative Strength Index (RSI)
- UPST 46.26
- ACLX 54.28
- Support Level
- UPST $48.00
- ACLX $82.64
- Resistance Level
- UPST $53.44
- ACLX $94.07
- Average True Range (ATR)
- UPST 3.02
- ACLX 3.64
- MACD
- UPST 0.82
- ACLX -0.81
- Stochastic Oscillator
- UPST 71.33
- ACLX 21.43
About UPST Upstart Holdings Inc.
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. Upstart's platform includes personal loans, automotive retail and refinance loans, home equity lines of credit, and small-dollar loans.
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.